Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action

Aromatase inhibitors (AIs) reduce breast cancer recurrence and prolong survival, but up to 30% of patients exhibit recurrence. Using a genome-wide association study of patients entered on MA.27, a phase III randomized trial of anastrozole versus exemestane, we identified a single nucleotide polymorp...

Descripción completa

Detalles Bibliográficos
Autores principales: Cairns, Junmei, Ingle, James N., Dudenkov, Tanda M., Kalari, Krishna R., Carlson, Erin E., Na, Jie, Buzdar, Aman U., Robson, Mark E., Ellis, Matthew J., Goss, Paul E., Shepherd, Lois E., Goodnature, Barbara, Goetz, Matthew P., Weinshilboum, Richard M., Li, Hu, Bari, Mehrab Ghanat, Wang, Liewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455128/
https://www.ncbi.nlm.nih.gov/pubmed/32701512
http://dx.doi.org/10.1172/jci.insight.137571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455128/
https://www.ncbi.nlm.nih.gov/pubmed/32701512
http://dx.doi.org/10.1172/jci.insight.137571

Ejemplares similares